News – Page 46 – Alligator Bioscience

2018-01-25

Alligator Bioscience contracts Theradex Oncology as clinical CRO for the upcoming ATOR-1015 phase I study

Lund, Sweden, 25 January – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals ...

2018-01-18

Lund, Sweden, 18 January – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals ...

2018-01-04

Lund, Sweden, 4 January, 2018 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing tumor-directed immunother ...

2018-01-03

Regulatory

Lund, Sweden, 3 January, 2018 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceut ...

2017-12-04

Appointment of Chief Medical Officer and VP Discovery Lund, Sweden, 4 December 2017 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biot ...

2017-11-21

Lund, Sweden, 21 November 2017 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceu ...

2017-11-13

Lund, Sweden, 13 November, 2017 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmace ...

2017-11-07

Regulatory

Lund, Sweden, 7 November 2017 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceut ...

2017-10-25

Regulatory

Three important collaborations in place. Results in November from ADC-1013 clinical phase I study. Significant events, July-September • Apte ...